Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LBRX
LB PHARMACEUTICALS INC COMMON STOCK
NASDAQ
$47.73
▼ DOWN 0.33% (-0.16)

KEY STATISTICS

Market Cap$1.37 B
52w High$50.16
52w Low$13.36
Dividend Yield—
Frequency—
P/E-27.59
Volume230.56K
Shares Out.28.68M

COMPANY

LEADERSHIP

Heather D. Turner
CHIEF EXECUTIVE
Heather D. Turner

COMPENSATION 2026

Salary$568,750
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$129,608
Total$11,884,985

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 11, 2025
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
49

PRICE TARGET

Target High$78.00
Target Low$36.00
Target Median$53.00
Target Consensus$51.86

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$47.73 ▼ DOWN 0.33% (−$0.16)
$46.50$47.25$48.00$48.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM47.73

About LB Pharmaceuticals Inc Common Stock

https://lbpharma.us ↗

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

INDUSTRY

Biotechnology

A PRODUCT LB PHARMACEUTICALS INC COMMON STOCK IS KNOWN FOR

LB-102
LB-102

LB-102 is a late-stage, oral small molecule drug by LB Pharmaceuticals, targeting schizophrenia and neuropsychiatric disorders, with potential to be a first-in-class benzamide antipsychotic approved in the U.S.

COMPETITORS

COMPETITOR
AXSM COMPARE
MPLT COMPARE
NBIX COMPARE
VNDA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
80
LISTED HERE
14
RANKED BY POSITION SIZE
VTI
0.00% · 684.0K
IWM
0.03% · 574.2K
XPH
1.09% · 134.1K
SCHA
0.02% · 117.3K
SBIO
0.70% · 35.5K
AVSC
0.04% · 27.6K
XRS2.DE
0.03% · 20.5K
BBC
1.01% · 11.0K
RSSL
0.03% · 10.7K
FHLC
0.01% · 8.1K
PILL
0.74% · 3.8K
JDOC
0.64% · 1.3K
URTY
0.01% · 908
SC0K.DE
0.03% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.18%
HOLDERS
120
TOP 12 OF 120 · RANKED BY POSITION SIZE
Deep Track Capital, LP
3.4M sh · $74.63M
Blackrock, Inc.
2.7M sh · $88.74M
Ra Capital Management, L.P.
2.2M sh · $71.68M
Tcg Crossover Management, LLC
1.8M sh · $45.28M
Jpmorgan Chase & Co
1.6M sh · $35.87M
Commodore Capital LP
1.5M sh · $36.99M
Caligan Partners LP
1.4M sh · $34.63M
Logos Global Management LP
1.2M sh · $26.71M
Vanguard Group Inc
1.1M sh · $24.77M
Nantahala Capital Management, LLC
1.1M sh · $34.17M
Balyasny Asset Management L.P.
923.7K sh · $22.78M
Alyeska Investment Group, L.P.
863.9K sh · $28.04M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BMO Capital OUTPERFORM Stifel BUY

SECTORS PEERS

PEERPRICE
SLDB$9.77COMPARE
DSGN$15.11COMPARE
ANNX$4.97COMPARE
AURA$7.40COMPARE
AUTL$2.34COMPARE
ALT$3.11COMPARE
RCKT$3.86COMPARE
LRMR$4.01COMPARE